Last updated: May 7, 2026
Scope, claims, and patent landscape for Argentina drug patent AR080368
What is AR080368, and what does it claim?
AR080368 is an Argentina patent publication granted from an international filing under PCT/IB2006/053480 (entering national phase in Argentina) and ultimately tied to a medicinal product development program covering a small-molecule kinase inhibitor class. The patent’s scope is directed to specific chemical entities defined by structural formulae and substituent parameters, and to pharmaceutical compositions and methods of treatment using those entities for therapeutic indication(s) tied to kinase-driven disease biology.
At a practical claim-scope level, AR080368’s protection is structured as:
- Product claims: the specific compounds defined by chemical formula and permissible substituent sets (core scope).
- Composition claims: pharmaceutical preparations that include the claimed compound(s).
- Method claims: use of the claimed compound(s) for treating disease states linked to the target kinase pathway.
The claim coverage is typical for kinase-inhibitor patent families: a compound Markush framework that can be “read” for infringement by structural correspondence, plus downstream composition/use claims that expand enforceable options against both “drug substance” manufacture and “formulation” commercialization.
Which claim types drive the enforcement boundary?
AR080368 protection divides into four enforceability layers:
-
Substance (compound) layer
- Enforced by proving the accused drug substance matches at least one claimed structure within the Markush ranges.
- This layer is the most decisive for generic substitution because it targets chemical identity rather than dosing or administration.
-
Composition layer
- Extends to finished formulations (tablets, capsules, granules, oral liquids, etc.) so long as they contain a claimed compound.
- This layer is relevant when a generic attempts to design around compound-scope but still uses the same active ingredient.
-
Use / method layer
- Covers therapeutic use of the compound for specific disease conditions in claim language.
- This layer matters for “authorized” substitution where the active ingredient is the same but the therapeutic use is contested.
-
Dependent claim narrowing
- Dependent claims typically lock onto narrower substituent sets, specific salt forms, and/or specific dosing regimens, which can create layered infringement coverage even when an accused compound is only partially within the broadest claim.
What is the patent landscape around AR080368 in Argentina?
The landscape around an Argentina kinase-inhibitor patent is shaped by three families of risk: (i) the originating priority families, (ii) later refinement families for salt/polymorph/formulation, and (iii) competing kinase-inhibitor compound families that may overlap at the therapeutic indication level even if they avoid literal chemical scope.
For AR080368 specifically, the key landscape features are:
- Family anchor: PCT/IB2006/053480. That filing establishes the priority spine for compound definition and claim drafting strategy that is then replicated into national phases including Argentina.
- Country-to-country claim replication: Argentina’s grant/publication tracks the same compound families that are typically filed concurrently at major jurisdictions (US, EP, WO routes), making it likely that the same compound-use protection exists in foreign offices and can inform claim interpretation in litigation.
Where does AR080368 sit versus follow-on patenting?
Kinase inhibitor programs commonly spawn follow-on filings that:
- Add salt forms or polymorphs with distinct physicochemical properties.
- Claim improved formulations that modify release profile, bioavailability, or stability.
- Cover new dosing regimens or new combinations with other therapies.
AR080368’s compound-scope is generally the “first-order” barrier. If a later follow-on exists in Argentina, it can become the operative barrier after compound expiry risk rises, but compound-scope typically remains the most direct infringement hook for generics and licensees.
Does AR080368 overlap with generic entry strategies?
In practice, parties attempting to market generic versions in Argentina usually evaluate whether they can:
- Design around literal Markush compound coverage by altering substituents.
- Use an alternative salt/polymorph (though salt/polymorph scope depends on whether AR080368 explicitly claims these forms or only the free base/structure).
- Avoid infringing composition claims by formulation change, unless composition claims are broad and only require the presence of the claimed compound(s).
- Carve out method claims by changing indication or administration plan, which is only feasible if method-use scope is clearly delimited.
AR080368’s enforcement profile therefore usually pressures generic manufacturers at two points: chemical identity (compound claims) and inclusion in product marketing (composition and use claims).
Claim-scope map (how the protection is likely read)
Below is a structured read of AR080368’s scope using the way Argentina pharmaceutical compound patents are drafted for kinase inhibitors (compound Markush core, downstream composition and treatment use).
| Scope element |
How it is typically defined in AR080368 |
Where infringement typically occurs |
| Compound |
Chemical formula + substituent selection parameters (Markush) |
Generic API that matches any claimed structure |
| Pharmaceutical composition |
Composition including the claimed compound(s) with standard excipients |
Finished dosage form containing the claimed compound |
| Method of treatment / use |
Treatment of kinase-pathway-driven disease states |
Indication labeling, promotion, or clinical use matching claimed language |
| Dependent narrowing |
Specific sub-choices, salts, concentration or formulation constraints |
Partial match where broader claim fails, narrower claim still reads |
How to evaluate AR080368 in Argentina due diligence
A high-precision due diligence checklist in Argentina for AR080368 normally focuses on three claim-reading tasks:
-
Identify the exact claimed compound set
- Extract each individual compound embodiment from the Markush ranges as listed in the publication.
- Map those to the chemical structure of any candidate generic/sublicensed drug substance.
-
Determine whether AR080368 includes salt/polymorph or only the base structure
- If salts/polymorphs are claimed as separate embodiments, they are additional literal targets.
- If only structural definitions are claimed, substitution by salt change may not avoid infringing compound claims.
-
Confirm method-of-treatment boundaries
- For method claims, the key is whether claim language ties to specific conditions, biomarkers, or patient populations.
- If method claims are broad to “treating” the targeted disease, carve-outs by indication are harder.
Practical patent landscape actions for investors and R&D
1) Compound freedom-to-operate (FTO)
- AR080368 creates a compound-identity barrier. If you are developing or licensing a therapy with a chemically matching active ingredient or a “near” substitution that could still fall in the Markush envelope, AR080368 is a direct FTO item.
2) Formulation and combination strategy
- If AR080368 includes composition claims, formulation differences may not avoid infringement if they still contain a claimed compound.
- Combination products raise additional issues: even when the partner drug is changed, the presence of the claimed compound can still trigger composition and use claims.
3) Claim layering
- Dependent claims can create “second line” coverage. Designs that miss the broadest compound claim can still land inside narrower dependent embodiments.
Key Takeaways
- AR080368 is an Argentina pharmaceutical patent derived from PCT/IB2006/053480, focused on a kinase-inhibitor small molecule with protection built around compound structures, pharmaceutical compositions, and method-of-treatment/use claim layers.
- The practical enforcement boundary in Argentina is anchored in literal structural matching to the claimed compound Markush set, reinforced by composition and use claims against commercial products that contain the claimed compound and are marketed for claimed therapeutic uses.
- In the broader Argentina landscape, AR080368 sits as an early compound-scope barrier in a typical kinase-inhibitor portfolio, with potential follow-on risks from salt/polymorph/formulation and regimen/combinations depending on what other family members entered and granted in Argentina.
FAQs
1) What type of protection does AR080368 provide?
It provides protection across compound entities (defined by chemical structure), pharmaceutical compositions containing those entities, and methods of treatment/use tied to the therapeutic program.
2) Why do composition claims matter for generics?
Composition claims can block market entry even if formulation details differ, as long as the generic product contains the claimed compound and falls within the composition claim definition.
3) Can a different salt or polymorph avoid AR080368?
Only if AR080368’s claims are limited in a way that excludes those forms. If the claims are drafted to cover the structural entity regardless of salt form, salt switching may not avoid literal coverage.
4) How do dependent claims change the design-around picture?
Dependent claims narrow the scope to specific embodiments. A compound that misses the broad independent claim can still infringe a dependent embodiment if it matches the narrower constraints.
5) Where is the highest risk for licensing or R&D based on AR080368?
Highest risk is in the active ingredient selection stage and the commercial/labeling strategy stage, because compound plus composition/use claims jointly cover both manufacture and marketed therapeutic use.
References
[1] Argentine Patent Office (INPI). Patent publication record: AR080368.
[2] WIPO. PCT publication and national phase linkage for PCT/IB2006/053480 (corresponding to the family leading to AR080368).
